COMMENT: Alkermes Needs New Strategy In Wake Of Trial Failures

Following the failure of two pivotal studies, Alkermes is unlikely to keep ALKS 5461 alive and must instead redefine its strategy, says Datamonitor Healthcare lead analyst Daniel Chancellor.